Enanta Pharmaceuticals, Inc. Initiates Phase 1 Study Of MRSA Infection Candidate EDP-788
Published: Jan 13, 2014
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the initiation of a Phase 1 clinical study of EDP-788, Enanta’s investigational compound for MRSA (methicillin-resistant Staphylococcus aureus) infections.
Help employers find you! Check out all the jobs and post your resume.